Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. (Q37406658)
Jump to navigation
Jump to search
scientific article published on 05 March 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. |
scientific article published on 05 March 2009 |
Statements
Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation (English)
Christos Christodoulou
Ioannis Kostopoulos
Evangelos Lianos
Evangelos Briasoulis
Helen Gogas
Evangelia Razis
Dimosthenis V Skarlos
Study of the Hellenic Cooperative Oncology Group
George Fountzilas